269 related articles for article (PubMed ID: 33893071)
41. Downregulation of miR-124 predicts poor prognosis in pancreatic ductal adenocarcinoma patients.
Sun B; Liu X; Gao Y; Li L; Dong Z
Br J Biomed Sci; 2016 Oct; 73(4):152-157. PubMed ID: 27922430
[TBL] [Abstract][Full Text] [Related]
42. A Plasma-Derived Protein-Metabolite Multiplexed Panel for Early-Stage Pancreatic Cancer.
Fahrmann JF; Bantis LE; Capello M; Scelo G; Dennison JB; Patel N; Murage E; Vykoukal J; Kundnani DL; Foretova L; Fabianova E; Holcatova I; Janout V; Feng Z; Yip-Schneider M; Zhang J; Brand R; Taguchi A; Maitra A; Brennan P; Max Schmidt C; Hanash S
J Natl Cancer Inst; 2019 Apr; 111(4):372-379. PubMed ID: 30137376
[TBL] [Abstract][Full Text] [Related]
43. Plasma MicroRNAs as Novel Biomarkers for Patients with Intraductal Papillary Mucinous Neoplasms of the Pancreas.
Permuth-Wey J; Chen DT; Fulp WJ; Yoder SJ; Zhang Y; Georgeades C; Husain K; Centeno BA; Magliocco AM; Coppola D; Malafa M
Cancer Prev Res (Phila); 2015 Sep; 8(9):826-34. PubMed ID: 26314797
[TBL] [Abstract][Full Text] [Related]
44. Validation of biomarkers that complement CA19.9 in detecting early pancreatic cancer.
Chan A; Prassas I; Dimitromanolakis A; Brand RE; Serra S; Diamandis EP; Blasutig IM
Clin Cancer Res; 2014 Nov; 20(22):5787-95. PubMed ID: 25239611
[TBL] [Abstract][Full Text] [Related]
45. Serum high mobility group box-1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma.
Chung HW; Lim JB; Jang S; Lee KJ; Park KH; Song SY
Cancer Sci; 2012 Sep; 103(9):1714-21. PubMed ID: 22703527
[TBL] [Abstract][Full Text] [Related]
46. Novel serum protein biomarker panel for early diagnosis of pancreatic cancer.
Byeon S; McKay MJ; Molloy MP; Gill AJ; Samra JS; Mittal A; Sahni S
Int J Cancer; 2024 Jul; 155(2):365-371. PubMed ID: 38519999
[TBL] [Abstract][Full Text] [Related]
47. Specific MAPK-Associated MicroRNAs in Serum Differentiate Pancreatic Cancer from Autoimmune Pancreatitis.
Akamatsu M; Makino N; Ikeda Y; Matsuda A; Ito M; Kakizaki Y; Saito Y; Ishizawa T; Kobayashi T; Furukawa T; Ueno Y
PLoS One; 2016; 11(7):e0158669. PubMed ID: 27380024
[TBL] [Abstract][Full Text] [Related]
48. Circulating Protein Biomarkers for Use in Pancreatic Ductal Adenocarcinoma Identification.
Lindgaard SC; Sztupinszki Z; Maag E; Chen IM; Johansen AZ; Jensen BV; Bojesen SE; Nielsen DL; Hansen CP; Hasselby JP; Nielsen KR; Szallasi Z; Johansen JS
Clin Cancer Res; 2021 May; 27(9):2592-2603. PubMed ID: 33737308
[TBL] [Abstract][Full Text] [Related]
49. Serum CA19-9, cathepsin D, and matrix metalloproteinase-7 as a diagnostic panel for pancreatic ductal adenocarcinoma.
Park HD; Kang ES; Kim JW; Lee KT; Lee KH; Park YS; Park JO; Lee J; Heo JS; Choi SH; Choi DW; Kim S; Lee JK; Lee SY
Proteomics; 2012 Dec; 12(23-24):3590-7. PubMed ID: 23065739
[TBL] [Abstract][Full Text] [Related]
50. miR-18a and miR-106a Signatures in Plasma Small EVs Are Promising Biomarkers for Early Detection of Pancreatic Ductal Adenocarcinoma.
Xu X; Bhandari K; Xu C; Morris K; Ding WQ
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108374
[TBL] [Abstract][Full Text] [Related]
51. Development and Multiple Validation of the Protein Multi-marker Panel for Diagnosis of Pancreatic Cancer.
Kim Y; Yeo I; Huh I; Kim J; Han D; Jang JY; Kim Y
Clin Cancer Res; 2021 Apr; 27(8):2236-2245. PubMed ID: 33504556
[TBL] [Abstract][Full Text] [Related]
52. Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics.
Yoneyama T; Ohtsuki S; Honda K; Kobayashi M; Iwasaki M; Uchida Y; Okusaka T; Nakamori S; Shimahara M; Ueno T; Tsuchida A; Sata N; Ioka T; Yasunami Y; Kosuge T; Kaneda T; Kato T; Yagihara K; Fujita S; Huang W; Yamada T; Tachikawa M; Terasaki T
PLoS One; 2016; 11(8):e0161009. PubMed ID: 27579675
[TBL] [Abstract][Full Text] [Related]
53. A pilot study to develop a diagnostic test for pancreatic ductal adenocarcinoma based on differential expression of select miRNA in plasma and bile.
Cote GA; Gore AJ; McElyea SD; Heathers LE; Xu H; Sherman S; Korc M
Am J Gastroenterol; 2014 Dec; 109(12):1942-52. PubMed ID: 25350767
[TBL] [Abstract][Full Text] [Related]
54. Early detection of pancreatic cancer by liquid biopsy "PANLIPSY": a french nation-wide study project.
Bardol T; Dujon AM; Taly V; Dunyach-Remy C; Lavigne JP; Costa-Silva B; Kurma K; Eslami-S Z; Cayrefourcq L; Canivet C; Muscari F; Bournet B; Alix-Panabières C
BMC Cancer; 2024 Jun; 24(1):709. PubMed ID: 38853244
[TBL] [Abstract][Full Text] [Related]
55. MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma.
Jamieson NB; Morran DC; Morton JP; Ali A; Dickson EJ; Carter CR; Sansom OJ; Evans TR; McKay CJ; Oien KA
Clin Cancer Res; 2012 Jan; 18(2):534-45. PubMed ID: 22114136
[TBL] [Abstract][Full Text] [Related]
56. Diagnostic and Prognostic Performance of MicroRNA-25, Carbohydrate Antigen 19-9, Carcinoembryonic Antigen, and Carbohydrate Antigen 125 in Pancreatic Ductal Adenocarcinoma.
Gong Y; Song L; Ou L; Lu YY; Huang X; Zeng Q
Iran J Med Sci; 2023 Jul; 48(4):401-413. PubMed ID: 37456201
[TBL] [Abstract][Full Text] [Related]
57. The ambiguous role of microRNA-205 and its clinical potential in pancreatic ductal adenocarcinoma.
Michael Traeger M; Rehkaemper J; Ullerich H; Steinestel K; Wardelmann E; Senninger N; Abdallah Dhayat S
J Cancer Res Clin Oncol; 2018 Dec; 144(12):2419-2431. PubMed ID: 30244390
[TBL] [Abstract][Full Text] [Related]
58. Plasma microRNAs as biomarkers of pancreatic cancer risk in a prospective cohort study.
Duell EJ; Lujan-Barroso L; Sala N; Deitz McElyea S; Overvad K; Tjonneland A; Olsen A; Weiderpass E; Busund LT; Moi L; Muller D; Vineis P; Aune D; Matullo G; Naccarati A; Panico S; Tagliabue G; Tumino R; Palli D; Kaaks R; Katzke VA; Boeing H; Bueno-de-Mesquita HBA; Peeters PH; Trichopoulou A; Lagiou P; Kotanidou A; Travis RC; Wareham N; Khaw KT; Ramon Quiros J; Rodríguez-Barranco M; Dorronsoro M; Chirlaque MD; Ardanaz E; Severi G; Boutron-Ruault MC; Rebours V; Brennan P; Gunter M; Scelo G; Cote G; Sherman S; Korc M
Int J Cancer; 2017 Sep; 141(5):905-915. PubMed ID: 28542740
[TBL] [Abstract][Full Text] [Related]
59. Circulating miR-483-3p and miR-21 is highly expressed in plasma of pancreatic cancer.
Abue M; Yokoyama M; Shibuya R; Tamai K; Yamaguchi K; Sato I; Tanaka N; Hamada S; Shimosegawa T; Sugamura K; Satoh K
Int J Oncol; 2015 Feb; 46(2):539-47. PubMed ID: 25384963
[TBL] [Abstract][Full Text] [Related]
60. Plasma miRNAs in diagnosis and prognosis of pancreatic cancer: A miRNA expression analysis.
Zhou X; Lu Z; Wang T; Huang Z; Zhu W; Miao Y
Gene; 2018 Oct; 673():181-193. PubMed ID: 29913239
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
